These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27269057)

  • 41. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
    Giuntini S; Pajon R; Ram S; Granoff DM
    Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.
    Daniels-Treffandier H; de Nie K; Marsay L; Dold C; Sadarangani M; Reyes-Sandoval A; Langford PR; Wyllie D; Hill F; Pollard AJ; Rollier CS
    PLoS One; 2016; 11(2):e0148840. PubMed ID: 26871712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine.
    Zollinger WD; Donets MA; Schmiel DH; Pinto VB; Labrie JE; Moran EE; Brandt BL; Ionin B; Marques R; Wu M; Chen P; Stoddard MB; Keiser PB
    Vaccine; 2010 Jul; 28(31):5057-67. PubMed ID: 20653107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
    Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
    N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
    Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
    J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.
    Sanders H; Norheim G; Chan H; Dold C; Vipond C; Derrick JP; Pollard AJ; Maiden MC; Feavers IM
    PLoS One; 2015; 10(10):e0140345. PubMed ID: 26466091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.
    Anderson AS; Hao L; Jiang Q; Harris SL; Jones TR; Perez JL; York L; Eiden J; Jansen KU
    Hum Vaccin Immunother; 2013 Mar; 9(3):471-9. PubMed ID: 23249817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor H binding protein (FHbp): An evaluation of genotypic diversity across
    Li Z; Murthy AK; Hao L; Andrew L; Anderson AS
    Hum Vaccin Immunother; 2024 Dec; 20(1):2409502. PubMed ID: 39387286
    [No Abstract]   [Full Text] [Related]  

  • 54. Development of an FHbp-CTB holotoxin-like chimera and the elicitation of bactericidal antibodies against serogroup B Neisseria meningitidis.
    Price GA; Bash MC
    Vaccine; 2018 Jan; 36(5):644-652. PubMed ID: 29287682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.
    Beernink PT; Shaughnessy J; Braga EM; Liu Q; Rice PA; Ram S; Granoff DM
    J Immunol; 2011 Mar; 186(6):3606-14. PubMed ID: 21325619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
    Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
    Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
    Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.